Polio Vaccine — CPB 0402 | AETNA Coverage Update

Aetna modified CPB 0402 covering polio vaccine coverage policy, effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated CPB 0402 to align its polio vaccine coverage policy with current CDC Advisory Committee on Immunization Practices (ACIP) recommendations. The modification covers CPT 90713 (inactivated poliovirus vaccine, IPV), CPT 90698 (DTaP-Hib-IPV combination), and CPT 90723 (DTaP-HepB-IPV combination). If your practice bills routine childhood immunizations or adult at-risk vaccinations under Aetna plans, this coverage policy affects your claim submission directly.

Quick-Reference Table

Aetna Polio Vaccine Coverage Criteria and Medical Necessity Requirements 2025

The foundation of CPB 0402 Aetna coverage policy is simple: Aetna considers the polio vaccine a medically necessary preventive service when administered according to ACIP recommendations. Medical necessity here is tied directly to CDC guidance — not to individual clinical judgment alone.

For routine childhood vaccination, Aetna covers IPV per the standard four-dose schedule: ages two months, four months, six to 18 months, and four to six years. CPT 90713 is your primary code for standalone IPV. CPT 90698 and CPT 90723 cover combination vaccines that include the IPV component alongside other antigens.

The oral polio vaccine (OPV) is a different story. Aetna's coverage policy limits OPV to three specific situations only. Outside those situations, OPV is not supported by ACIP guidance, and billing it as routine will get your claim denied.

The three covered OPV situations are narrow:

If you're billing OPV outside these three scenarios, you don't have a coverage argument under CPB 0402. Document your clinical reasoning clearly in the chart when OPV is used — especially for the parental refusal scenario, where the discussion of VAPP risk needs to be in the record.

For adults over 18, medical necessity for polio vaccination requires demonstrated increased exposure risk. This is not a blanket adult reimbursement situation. Aetna covers IPV for adults who fall into four specific high-risk categories.

The adult high-risk categories are:

For adults in these categories, prior authorization requirements may apply depending on the specific Aetna plan. Check the member's plan before administering and billing. The recommended adult schedule is two doses given one to two months apart, then a third dose six to 12 months later. Bill CPT 90713 for each IPV dose administered in this series.

The ICD-10-CM codes that pair with this coverage policy are Z23 for routine immunization encounters and Z20.89 for contact with or suspected exposure to communicable diseases, including poliomyelitis. Use Z20.89 when billing for adults with documented exposure risk. Use Z23 for routine pediatric vaccination encounters.

Coverage Indications at a Glance

Aetna Polio Vaccine Billing Guidelines and Action Items 2025

The effective date of September 26, 2025 is your trigger. Here's what to do before and after that date.

1. Audit your charge capture for CPT 90713, 90698, and 90723 now.
Pull your last 90 days of claims for these three codes under Aetna plans. Check that each claim paired the correct ICD-10 — Z23 for pediatric routine visits, Z20.89 for adult at-risk encounters. Mismatched diagnosis codes are a fast path to a claim denial.

2. Flag any OPV billing for immediate review.
If your practice administers OPV, confirm every recent claim falls into one of the three covered scenarios. If you've billed OPV for routine use, review those claims with your compliance officer before the September 26, 2025 effective date. Retroactive exposure is real here.

3. Build documentation triggers for adult high-risk billing.
For adult patients, the coverage argument lives in the documentation. Set up a structured note template that captures the specific exposure category — healthcare worker, outbreak member, lab worker, or traveler. Attach Z20.89 at the time of service, not as an afterthought.

4. Confirm prior authorization requirements by plan for adult vaccination.
Aetna plan designs vary. Before billing adult IPV as routine reimbursement, verify whether the specific plan requires prior authorization for the three-dose series. Your front desk or referral team should build a verification step for adult polio vaccine encounters.

5. Update your encounter forms and charge master if needed.
If CPT 90698 or 90723 aren't already in your charge master for pediatric combination vaccine billing, add them. These combination codes cover the IPV component within multi-antigen vaccines. Billing 90713 alone when you administered a combination product is both a billing accuracy issue and a potential undercoding problem.

6. Train clinical staff on OPV documentation requirements.
The parental refusal scenario for OPV is the one most likely to generate a claim denial if the chart doesn't show the VAPP risk discussion. Make sure physicians and nurses document that conversation explicitly — not just a checkbox, but a note that reflects what was discussed with the parent or caregiver.

7. Check your billing guidelines reference against the updated CPB 0402.
If your team uses an internal payer reference sheet for Aetna immunization billing, update it to reflect the September 26, 2025 changes. Out-of-date reference documents are how denial patterns get baked into your workflow without anyone noticing.

CPT, HCPCS, and ICD-10 Codes for Polio Vaccine Under CPB 0402

Covered CPT Codes (When Selection Criteria Are Met)

All three codes are covered when ACIP-based selection criteria are met. CPT 90713 is the standalone IPV code. CPT 90698 and 90723 are combination products — use them when the administered vaccine includes IPV as one component of a multi-antigen formulation.

Key ICD-10-CM Diagnosis Codes

Pair Z23 with pediatric IPV billing under the standard ACIP schedule. Pair Z20.89 with adult IPV billing when documenting occupational exposure, outbreak exposure, travel risk, or laboratory contact. Getting this pairing wrong is the single most common source of claim denial on these codes.